

2004 Substitution for form 1449A/P10 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				COMPLETE IF KNOWN	
				Application Number	10/730,704
				Filing Date	December 8, 2003
				First Named Inventor	R.P. Nargund et al.
				Group Art Unit	-- 16/14
				Examiner Name	SPINACK
Sheet	1	of	5	Attorney Docket Number	21151

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
PS			EP 0 920 864		PFIZER PRODUCTS INC.	06/09/1999
PS			WO 00/66578		PFIZER PRODUCTS INC.	11/09/2000
PS			WO 97/46250		SYNAPTIC PHARMACEUTICAL CORP.	12/11/1997
PS			WO 97/16189		MERCK & CO., Inc.	05/09/1997
PS			WO 96/40912		AMGEN Inc.	12/19/1996
PS			WO 97/06816		AMGEN Inc.	02/27/1997
PS			WO 97/18833		AMGEN Inc.	05/29/1997
PS			WO 98/28427		AMGEN Inc.	07/02/1998
PS			WO 02/060427		SEPRACOR Inc.	08/08/2002
PS			WO 02/060428		SEPRACOR Inc.	08/08/2002

Examiner Signature	<i>P. Smith</i>	Date Considered	9/17/06
-----------------------	-----------------	--------------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/730,704
Filing Date	December 8, 2003
First Named Inventor	R.P. Nargund et al.
Group Art Unit	--
Examiner Name	
Attorney Docket Number	21151

Sheet 2 of 5

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
PS			WO 00/76493	NAJARIAN	12/21/2000
PS			WO 01/52825	NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.	07/26/2001
PS			WO 01/01969	ENDORECHERCHE, INC.	01/11/2001
PS			WO 02/32897	PFIZER PRODUCTS INC.	04/25/2002
PS			WO 98/18481	MERCK & CO., Inc.	05/07/1988
PS			WO 02/068388	MERCK & CO., Inc.	09/06/2002
PS			WO 02/019998	ELI LILLY AND COMPANY	03/14/2002
PS			WO 98/32441	SANOFI	07/30/1998
PS			WO 02/28346	AVENTIS PHARMA S.A.	04/11/2002

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/730,704	
			Filing Date	December 8, 2003	
			First Named Inventor	R.P. Nargund et al.	
			Group Art Unit	--	
			Examiner Name		
Sheet	3	of	5	Attorney Docket Number	21151

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
PS	AA	Farrigan et al., Nature Reviews - Drug Discovery, Vol. 1 (2002), "Obesity market overview", pp. 257-258,
PS	AB	Bray et al., Obesity Research, Vol. 7 (1999), "Sibutramine produces dose-related weight loss", pp. 189-198,
PS	AC	Kopelman, Nature, Vol. 404 (2000), "Obesity as a medical problem", pp. 635-643,
PS	AD	Steinbeck, Internal Medicine Journal (2002), Vol. 32, "Obesity: the science behind the management", pp. 237-241,
PS	AE	Qu et al., Nature, Vol. 380 (1996), "A role for melanin-concentrating hormone in the central regulation of feeding behaviour", pp. 243-247,
PS	AF	Davidson et al., JAMA, Vol. 281 (1999), "Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat", pp. 235-242,
PS	AG	Douglas et al., Int'l J. of Obesity, Vol. 7 (1983), "Plasma phentermine levels, weight loss and side-effects", pp. 591-595,
PS	AH	Guy-Grand et al., The Lancet (1989), "Therapeutics: International trial of long-term dexfenfluramine in obesity", pp. 1142-1144,
PS	AI	Muccioli et al., Eur. J. of Pharmacol., Vol. 440 (2002), "Neuroendocrine and peripheral activities of ghrelin...", pp. 235-254,
PS	AJ	Chamorro et al., Int'l J. of Obesity, Vol. 26 (2002), "Appetite suppression based on selective inhibition of NPY receptors", pp. 281-298,
PS	AK	Balasubramaniam, The American J. of Surgery, Vol. 183 (2002), "Clinical potentials of neuropeptide Y family or hormones", pp. 430-434,
PS	AL	Guercioli, Int'l J. of Obesity, Vol. 21 (1997), Suppl. 3, "Mode of action of orlistat", pp. S12-S23,
PS	AM	Sletten et al., Current Therap. Res., Vol. 9 (1967), "Weight reduction with chlorphentermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy", pp. 570-575,
PS	AN	Kolakowska et al., Int'l Clinical Psychopharmacol., Vol. 2 (1987), "An open clinical trial of fenfluramine in chronic schizophrenia: A pilot study", pp. 83-88,
PS	AO	Pierson et al., J. Med. Chem., Vol. 40 (1997), "Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents", pp. 4302-4307,

Examiner Signature	<i>P. Spivack</i>	Date Considered	9/17/06
--------------------	-------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/730,704	
			Filing Date	December 8, 2003	
			First Named Inventor	R.P. Nargund et al.	
			Group Art Unit	--	
			Examiner Name		
Sheet	4	of	5	Attorney Docket Number	21151

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
PS	AP	Bray et al., Nature, Vol. 404 (2000), "Medicinal strategies in the treatment of obesity", pp. 672-677
PS	AQ	Kushner et al., Current Opinion in Gastroenterology, Vol. 18 (2002), "Obesity pharmacology: past, present, and future, pp. 213-220
PS	AR	MacNeil et al., Eur. J. of Pharmacol., Vol. 440 (2002), "The role of melanocortins in body weight regulation...", pp. 141-157.
PS	AS	Kirkham et al., Psychopharmacology, Vol. 153 (2001), "Synergistic effects (<i>sic</i>) of opioid and cannabinoid antagonists", pp. 267-270
PS	AT	Boozer et al., Metabolism, Vol. 50 (2001), "Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats", pp 889-893.
PS	AU	Wadden et al., Obesity Research, Vol. 8 (2000), "Effects of sibutramine plus orlistat in obese women following 1 year of treatment ..., pp. 431-437
PS	AV	Zhou et al., Society for Neuroscience Abstracts, Vol. 27 (2001), 31st annual meeting of the Society for Neuroscience, San Diego, CA, November 10-15, 2001, "Attenuation of withdrawal reaction by a selective melanocortin MC4 receptor antagonist ...", p. 599
PS	AW	Myrick et al., The American J. on Addictions, Vol. 10 (2001), "New developments in the pharmacotherapy of alcohol dependence", pp. 3-15.
PS	AX	Angehelescu et al., J. of Clin. Psychopharmacol., Vol. 22 (2000), "Add-on combination and maintenance treatment ..., pp. 521-524.
PS	AY	Matson et al., Am. J. Physiol. Regulatory Integrative Comp. Physiol., Vol. 278 (2000), "Cholecystokinin and leptin act synergistically to reduce body weight", pp. R882-R890
PS	AZ	Le et al., Alcohol & Alcoholism, Vol. 31 (1996), "Use of serotonin (5-HT) and opiate-based drugs in the pharmacotherapy of alcohol dependence ...", pp. 27-32.
PS	BA	Chiesi et al., TRENDS in Pharmacological Sciences, Vol. 22 (2001), "Pharmacotherapy of obesity: targets and perspectives", pp 247-254.
PS	BB	Atkinson et al., Obesity Research, Vol. 3 (1995), "Combined drug treatment of obesity", pp. 497S-500S.
PS	BC	Raffa et al., Am. J. Med., Vol. 101, Suppl. 1A (1996), "A novel approach to the pharmacology of analgesics", pp. 40S-46S
PS	BD	Fernandez-Lopez et al., Drugs, Vol. 62 (2002), "Pharmacological approaches for the treatment of obesity", pp. 915-944

Examiner Signature	<i>P. Sawack</i>	Date Considered	9/17/06
--------------------	------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/730,704	
			Filing Date	December 8, 2003	
			First Named Inventor	R.P. Nargund et al.	
			Group Art Unit	--	
			Examiner Name		
Sheet	5	of	5	Attorney Docket Number	21151

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
PS	BE	Lu et al., Peptides, Vol. 21 (2000), "Leptin resistance in obesity is characterized by decreased sensitivity to proopiomelanocortin products", pp. 1479-1485 -
PS	BF	Dunbar et al., Brain Research Bulletin, Vol. 50 (1999), "Leptin-induced increase in sympathetic nervous and cardiovascular tone is mediated by proopiomelanocortin (POMC) products", pp. 215-221 .
PS	BG	Bickerdike et al., Eur. J. of Pharmacology, Vol. 271 (1994), "The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze", pp. 403-411 .
PS	BH	Proietto et al., Exp. Opin. Invest. Drugs, Vol. 9 (2000), "Novel anti-obesity drugs", pp. 1317-1326,
PS	BI	Parker et al., Eur. J. of Pharmacology, Vol. 440 (2002), "Neuropeptide Y receptors as targets for anti-obesity drug development ...", pp. 173-187,
PS	BJ	Rowland et al., Psychopharmacology, Vol. 159 (2001), "Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine ...", pp. 111-116 .
PS	BK	Sabath Silva et al., Revista de Investigacion Clinica, Vol. 54 (2002), "Leptina", pp. 161-165 .
PS	BL	Chaki et al., Exp. Opin. Ther. Patents, Vol. 11 (2001), "Recent advances in feeding suppressing agents...", pp. 1677-1692 .
PS	BM	Pomonis et al., The J. of Neuroscience, Vol. 17 (1997), "Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade ...", pp. 5175-5182 .
PS	BN	Lalonde et al, Physiol. & Behavior, Vol. 80 (2004), "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice", pp. 415-420 .
PS	BO	Turton et al., Nature, Vol. 379 (1996), "A role for glucagon-like peptide-1 in the central regulation of feeding", pp. 69-72 .
PS	BP	Erickson et al., Nature, Vol. 381 (1996), "Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y", pp.; 415-418 ,
PS	BQ	Lonnqvist et al., Nature Medicine, Vol. 1 (1995), "Overexpression of the obese (ob) gene in adipose tissue of human obese subjects", pp 950-953 .
PS	BR	De Vos et al., J. of Biol. Chem., Vol. 270 (1995), "Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake", pp. 15958-15961,

Examiner Signature	<i>P. Spivack</i>	Date Considered	9/17/06
--------------------	-------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 14498/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary).

COMPLETE IF KNOWN

Application Number	10/730,704
Filing Date	December 8, 2003
First Named Inventor	Ravi P. Nargund et al.
Group Art Unit	1614
Examiner Name	P.G. Spivack

Sheet	2	of	2	Attorney Docket Number	21151
-------	---	----	---	------------------------	-------

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	P. Spindick	Date Considered	4/17/06
--------------------	-------------	-----------------	---------

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005